Fewer than one in 10 patients eligible to benefit from weight-loss injections including Wegovy can access them, warns the World Health Organization as it publishes its inaugural recommendations on the medications.
Given more than one billion individuals worldwide now obese, it is advocating for increased and just access to this class of drugs.
Per estimates, in excess of 2,000,000,000 could be obese by 2030 unless action is taken.
"The latest guidelines recognises that obesity is a lifelong illness that can be addressed with thorough and lifelong care," said its chief Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and supply-chain constraints are major barriers to widespread access to the injections that can help people shift significant body mass, says the body.
GLP-1 Therapy Scarcity
Even in the present best projected outlook, the production of GLP-1 therapies could only cover about 100 million people – under 10% of those who need them, as stated by the health organization.
The advice urges governments and firms to increase availability, by measures including patent sharing.
The intellectual property rights on the active ingredient – the primary ingredient of a leading brand – is scheduled to end in several nations in 2026.
The Way Obesity Drugs Function
These medications imitate a body's own hormone to slow digestion, reduce hunger and increase the sense of being full so users consume fewer calories.
People typically begin shedding pounds within a few weeks of commencing the once-weekly jabs.
Research suggests people may put most of the weight back on a year later of halting the treatment, as their usual appetite come back.
Being overweight or obese elevates your likelihood for contracting medical conditions, such as diabetes, cardiovascular issues, brain attack, and specific cancers.
Obesity affects people in countries worldwide and was associated with over three and a half million deaths worldwide in 2024, according to the WHO.
